BioPharma, Pharma Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds By Frank Vinluan
Health Tech, Startups Ilant Health Raises Extended Seed Round of $5.5M for Obesity Management Platform By Marissa Plescia
Consumer / Employer, Payers MedCity FemFwd: Inside the EveryBODY Covered Campaign Aiming To Improve Obesity Care Coverage By Marissa Plescia
Daily, MedCity Influencers GLP-1s Alone Are Not the Answer to America’s Obesity and Chronic Illness Crises By Lauren Driscoll
Sponsored Post Build My Health Webinar Highlights New Age for Physician Practices with Rise of GLP1 Drugs for Obesity By Stephanie Baum
MedCity Influencers, Health Services Let’s Make This the Last World Obesity Care Week By Glen Tullman
BioPharma, Pharma Novo Nordisk Obesity Pill Flashes the Potential to Beat Wegovy in Weight Loss By Frank Vinluan
BioPharma, Pharma Viking Therapeutics Obesity Drug’s Data Raise Best-in-Class Expectations By Frank Vinluan
MedCity Influencers We’ve Actually Treated Tens of Thousands of People on Ozempic to Date – Here’s What Really Happens and What It Likely Means for Solving Our Obesity Epidemic By Dr. Jeff Stanley
BioPharma, Pharma Roche Lines Up $2.7B Acquisition to Join Chase for New Diabetes, Obesity Drugs By Frank Vinluan
BioPharma, Pharma Carmot’s IPO Filing Makes Case for Bias in Drugging Key Obesity, Diabetes Targets By Frank Vinluan
